IDNA — iShares Genomics Immunology and Healthcare ETF
Data updated: 2026-06-25
IDNA — iShares Genomics Immunology and Healthcare ETF. Holdings, fees, performance and SEC filings.
IDNA Fund Overview
IDNA — iShares Genomics Immunology and Healthcare ETF is a US ETF managed by iSHARES TRUST, categorised as Global (incl. US) Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: iSHARES TRUST
- Category: Global (incl. US) Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $160.48M
- 1-year return: 41.5%
- Ticker: IDNA
- SEC CIK: 0001100663
- SEC series ID: S000065599
- Share class ID: C000212225
IDNA Holdings
Top 10 holdings of iShares Genomics Immunology and Healthcare ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 20.98% |
| Revolution Medicines, Inc. | 6.85% |
| Moderna, Inc. | 6.28% |
| Ipsen SA | 5.24% |
| Bayer Aktiengesellschaft | 4.38% |
| Takeda Pharmaceutical Company Limited | 4.22% |
| Merck & Co., Inc. | 4.15% |
| Gsk PLC | 4.12% |
| BioNTech SE | 4.07% |
| Roche Holding AG | 3.99% |
IDNA Portfolio Allocation
Asset-class allocation of iShares Genomics Immunology and Healthcare ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 95.1% |
| Cash & Equivalents | 21.0% |
| Other | 4.2% |
IDNA Performance
Total returns for IDNA (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 12.5% |
| 1 year | 41.5% |
| 3 years (annualised) | 9.0% |
| 5 years (annualised) | -8.5% |
IDNA Risk Information
Risk metrics for IDNA, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 19.4%
IDNA Costs and Fees
IDNA costs about $47 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.47%
- Gross expense ratio: 0.47%
- Portfolio turnover: 49%
- Brokerage commissions: 5.45 bps of average net assets (SEC N-CEN)
IDNA Cashflows
Over the 12 months to 2026-04, iShares Genomics Immunology and Healthcare ETF had net inflows of $7.50M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $7.71M |
| 2026-03 | $3.00M |
| 2026-02 | $3.09M |
| 2026-01 | $0 |
| 2025-12 | $4.03M |
| 2025-11 | −$5.18M |
IDNA Debt Constituents
No individual debt constituents are reported in iShares Genomics Immunology and Healthcare ETF's latest SEC N-PORT filing.
IDNA Prospectus and SEC Filings
Official iShares Genomics Immunology and Healthcare ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-11-21
- Prospectus (485BPOS) — filed 2024-11-22
- Prospectus supplement (497) — filed 2024-11-29
- Portfolio holdings (N-PORT) — filed 2026-06-25
- Portfolio holdings (N-PORT) — filed 2026-03-25
- Portfolio holdings (N-PORT) — filed 2025-12-29
- Annual census (N-CEN) — filed 2025-10-14
- Annual census (N-CEN) — filed 2024-10-15
Related Funds
Other Global (incl. US) Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.